We're proud to share that Model Medicines has been named to Fierce Medtech's 2025 "Fierce 15"—a distinction that highlights the most groundbreaking private companies in healthcare. This recognition places us in the company of leaders in AI-driven drug development, including Recursion Pharmaceuticals, Insilico Medicine, Genesis Therapeutics, and Generate Biomedicines. These organizations are redefining how therapeutics are discovered and advanced.

What This Means for Model Medicines

This honor recognizes our mission to transform drug discovery through the use of artificial intelligence. At Model Medicines, we’ve built GALILEO™, a comprehensive AI platform that brings together target identification, molecule generation, and early-stage safety profiling. GALILEO™ recently evaluated 53 trillion virtual compounds, selected a dozen promising candidates, synthesized all 12, and achieved a 100% hit rate in antiviral screening. You can read the full preprint on these findings here.

These results underscore the strength of our platform and our commitment to developing treatments that target shared molecular drivers across various diseases.

AmesNet: Raising the Bar for Safety Prediction

Beyond discovery, our technology stack includes AmesNet, an advanced ADMET modeling tool that excels in predicting mutagenic risks. AmesNet outperforms traditional QSAR models in both sensitivity and generalization, enabling us to assess compound safety earlier in the pipeline and reduce downstream development risk. You can read more about AmesNet in our preprint here.